Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort

<b>Background/Objectives</b>: The objective was to compare the results of segmentectomy and lobectomy in the treatment of c-stage IA lung cancer in terms of tumor recurrence and 5-year survival. <b>Methods:</b> An observational study was performed using 3533 patients included in the registry of the Spanish VATS Group (GEVATS) of the Spanish Society of Thoracic Surgery (SECT) between 2016 and 2018. A total of 1004 lobectomies and 83 segmentectomies in c-stage IA were selected. Two comparable groups were selected through 2:1 propensity score matching with patient-, tumor- and surgery-related variables, leaving 166 lobectomies and 83 segmentectomies. Tumor recurrence was analyzed by Fisher's test and overall, cancer-specific, recurrence-free and disease-free survival by Kaplan-Meier and Log-rank tests. <b>Results:</b> Overall recurrence was 23.7% in both groups, with a predominance of locoregional recurrence in segmentectomy (16.2% vs. 11.2%) and distant recurrence in lobectomy (12.5% vs. 7.5%). There was no difference between the two groups in any of the survival types. Overall survival at 5 years was 73.5% (95% CI: 65.5-82.4%) in the lobectomy group vs. 73.1% (95% CI: 60.1-88.9%) in the segmentectomy group. <b>Conclusions:</b> Anatomic segmentectomy may be a valid option in the treatment of c-stage IA lung cancer since the recurrence and long-term survival outcomes compared to lobectomy are equivalent.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-03-26
DOI
https://doi.org/10.3390/jcm14072267
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort

Jon A. Lizarbe, Arantza Fernández-Monge, Laura Sánchez-Moreno, Fernando Ascanio et al.
Journal of Clinical Medicine
Lung Cancer Diagnosis and Treatment
article

Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort

Jon A. Lizarbe, Arantza Fernández-Monge, Laura Sánchez-Moreno, Fernando Ascanio, Borja Aguinagalde, José Luis Recuero Díaz, Raúl Embún Flor, Juan A. Ferrer-Bonsoms, Iker López, Julio Sesma
article en

Abstract

<b>Background/Objectives</b>: The objective was to compare the results of segmentectomy and lobectomy in the treatment of c-stage IA lung cancer in terms of tumor recurrence and 5-year survival. <b>Methods:</b> An observational study was performed using 3533 patients included in the registry of the Spanish VATS Group (GEVATS) of the Spanish Society of Thoracic Surgery (SECT) between 2016 and 2018. A total of 1004 lobectomies and 83 segmentectomies in c-stage IA were selected. Two comparable groups were selected through 2:1 propensity score matching with patient-, tumor- and surgery-related variables, leaving 166 lobectomies and 83 segmentectomies. Tumor recurrence was analyzed by Fisher's test and overall, cancer-specific, recurrence-free and disease-free survival by Kaplan-Meier and Log-rank tests. <b>Results:</b> Overall recurrence was 23.7% in both groups, with a predominance of locoregional recurrence in segmentectomy (16.2% vs. 11.2%) and distant recurrence in lobectomy (12.5% vs. 7.5%). There was no difference between the two groups in any of the survival types. Overall survival at 5 years was 73.5% (95% CI: 65.5-82.4%) in the lobectomy group vs. 73.1% (95% CI: 60.1-88.9%) in the segmentectomy group. <b>Conclusions:</b> Anatomic segmentectomy may be a valid option in the treatment of c-stage IA lung cancer since the recurrence and long-term survival outcomes compared to lobectomy are equivalent.

Journal of Clinical MedicineVol. 14(7)
Marqués de Valdecilla University Hospital (ES), Biogipuzkoa Health Research Institute (ES), Hospital Universitario Miguel Servet (ES), Vall d'Hebron Hospital Universitari (ES), Instituto de Investigación Sanitaria Aragón (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Universidad de Navarra (ES)
Openalex Percentile: Top 91%
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.